Those with preserved EF seemed to get more protection against HF events/CV death than those with reduced or unknown EF.

It’s a known problem, but treatment hasn’t improved in 20 years. Experts say it’s time for protocolized systems of care, they ...

With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.

The procurement and perfusion method, areas that are rapidly evolving, will likely play a role in the success of DCD transplants.

Though recombinant factor VIIa didn’t improve outcomes overall, treating very early and in those with a spot sign on CT may ...

The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.

Neither stenting nor endarterectomy provided a boost versus medical therapy alone in patients with asymptomatic stenosis.

A bundle of protocols including patient education, skin prep, and glove changes reduced infections at a large US surgical ...

Overcoming clinical inertia around starting and intensifying antihypertensive drugs is key, a researcher says.

Transparency is needed to improve equity, though it can be awkward to talk about salary, says Thomas MacGillivray.

Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and ...

Observational data point to the scope of opportunity that lies in GLP-1 drugs, SGLT2 inhibitors, and nonsteroidal MRAs.